Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2007

View Archived Issues

Natural toxin shows potential against prostate cancer in vitro

New agents for treating acne and alopecia reported in recent Pfizer patent

Recent patents describe novel therapeutic agents for respiratory disorders

Novel treatment option for irritable bowel syndrome disclosed by Astellas

Identification of c-Src protein kinase inhibitors as a novel class for anti-dengue virus therapy

Anti-ribosomal P antibodies may explain CNS symptoms in SLE

Aeterna Zentaris rounds up 2006 clinical progress

Formulation work required for CRD-5 following phase I/II findings

Peplin updates progress of PEP-005 Topical program

Studies show Radilex may stimulate hematopoietic stem cells

TM-30339 advanced into clinical trials for obesity

Positive data reported from phase Ib study of TASQ

Oxford BioMedica to acquire Oxxon Therapeutics

Schering-Plough to acquire Organon Biosciences

Sym-001, first recombinant polyclonal antibody to enter clinical trials

Array BioPharma reports on anticancer activity of its p38 MAPK inhibitor

Biomarker studies test AZD-0530's potential in managing bone metastasis

Cardium Therapeutics closes private placement financing

FDA updates safety information for erythropoiesis-stimulating agents

Pemetrexed combinations found highly effective against NSCLC cells

SNS-314 shows consistent and dose-dependent antitumor activity in mice

WX-671 plus 5-FU, gemcitabine or irinotecan reduce cancer metastasis and invasion

Nitoman launched in Germany

Xyrem approved in E.U. for narcolepsy with cataplexy

Approvable letter for Accretropin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...